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ABSTRACT 
Background: A short treatment course for multidrug-resistant tuberculosis (MR-TB) is not yet well codified in children in the 
Democratic Republic of Congo (DRC). The objective of this study was to evaluate a short MR-TB treatment course in children.  
Methods: A prospective study was performed from April 2015 (corresponding to the inclusion) through April 2017 (and the later 
initiation time point was April 2016) in the University Clinics of Kinshasa. Enrolled children were aged 0 to 15 years. The treatment 
duration was in general for 9 months, with 4 months of intensive phase treatment with Kanamycin, Levofloxacin, Isoniazid, 
Pyrazinamide, Prothionamide, Clofazimine and Ethambutol, and 5 months of continuous phase treatment with Levofloxacin, 
Pyrazinamide, Clofazimine and Ethambutol. Frequencies were reported for significant results.  
Results: A total of 21 children had MDR-TB (11 males and 10 females). Fifteen (71.43%) were bacteriological confirmed cases (by 
Xpert/MTB), and 6 (28.57%) were clinically diagnosed (MDR-TB contact with suggestive radiologic lesions); 2 patients were 
coinfected with HIV, 15 cases had pulmonary TB, and 6 had extrapulmonary TB. The main radiologic findings included TB cavity 
(3 cases), pleural effusion (5 cases), alveolar syndrome (8 cases), adenopathy (7 cases), and interstitial infiltration, fibrosis and 
miliary (2 cases each). The Ziehl control was negative before 4 months of treatment in the majority of the cases. Overall, 11 patients 
were cured, 7 completed the treatment, 2 died and 1 was lost to follow up. 
Conclusions: MDR-TB remains a challenge in children. A more comfortable, short treatment course is feasible in children in the 
DRC. It is necessary to verify this observation with a larger cohort of MDR-TB patients in pediatrics.  
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 Article Info: Received 19 Jan, 2018; Review Completed 9 March, 2018; Accepted 10 March, 2018; Available online 15 March, 2018 
Cite this article as: 
Loukia A, Joseph SD, Brian B, Nicole A, Zacharie K, Multidrug resistant tuberculosis in children in the democratic 
republic of Congo: first experience with a short treatment course in a university hospital, Journal of Drug Delivery 
and Therapeutics. 2018; 8(2):123-128 
DOI: http://dx.doi.org/10.22270/jddt.v8i2.1682  
*Address for Correspondence: Aketi Loukia, Department of Pediatrics, University Hospital of Kinshasa, Kinshasa, Democratic 




Multidrug-resistant tuberculosis (MDR-TB) is a major 
health problem. It is defined as TB resistant to at least 
isoniazid (INH) and rifampicin (Rif). In 2016, the 
number of MDR-TB cases estimated worldwide was 
480,000, but the estimated number was approximately 
10,4 million cases 
1
. The Democratic Republic of the 
Congo (DRC), which is one of 22 TB high-burden 
countries, reported 2,790 MDR-TB cases in the same 
year, which represents 2.2% of new TB cases and 11% 
of retreated cases 
1
. In children, the MDR-TB situation 
is unknown.  
There exists a relationship between the community TB 
prevalence and the proportion of cases found in 
children: the higher the prevalence, the greater the 
proportion 
2
. Therefore, in regards to the situation in 
adults, we can extrapolate that MDR-TB in children 
represents a serious burden for the community and 
national programs. Although guidelines for adults with 
MDR-TB are reasonably well-defined, little guidance is 
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available in children for national tuberculosis programs 
on planning and implementing MDR-TB services 
3
, or 
the guidelines focus mainly on individual patient care 
4, 
5
. In the DRC, a significant number of children with 
MDR-TB are not diagnosed and treated because there 
are challenges related to the microbiological diagnosis, 
and there are no drug formulations adapted for children 
in the second-line regimens. This treatment entails 
significant adverse events, with stigma and adherence 
challenges, and it requires an available adult to 
administer the treatment in children. To improve 
adherence and to render more comfortable treatment, 
long-term MDR-TB treatment is progressively being 
replaced by a short-term treatment course. In the DRC 
in adults, the 24 months of second-line therapy have 
been replaced by a shorter 9 month treatment, as used in 
other cohorts 
6, 7, 8, 9
. In children, there are no guidelines 
and no consensus regarding shorter second-line 
treatment regimens. The objective of this study is to 
describe the clinical profile and the efficacy of a short 
course treatment used in children with MDR-TB in the 
University Clinic of Kinshasa (UCK).  
METHODS 
This study was a prospective study. The cohort was 
identified at the time of their confirmed or presumptive 
MDR-TB diagnosis and then followed prospectively. A 
cohort of children were followed until their diagnosis of 
MDR-TB. They were recruited from April 2015 to 
December 2016, the later time point of follow up was 
May 2017. This period corresponded with a period of 
intense implementation of MDR-TB guidelines in the 
city. The study occurred at the University hospital of 
Kinshasa, which is a referral hospital. It included 
children aged 0 to 15 years who came from the centers 
for TB diagnosis and treatment (CSDT), from the 
national TB coordination center, or from different 
services within the UCK. They were transferred to the 
Pneumology unit of the UCK pediatric department 
based on suspicion for TB, for contact with a known 
MDR-TB case, for not responding to first-line therapy, 
for recurrence in a child previously treated, or for 
treatment after a MDR-TB confirmed diagnosis.  
In children, a MDR-TB case was defined as a child with 
proven bacteriology or Xpert-confirmed MDR-TB or 
who had contact with a MDR-TB patient and had 
suggestive clinical or radiologic lesions 
10
. Xpert MTB-
Rif analysis was performed at the national laboratory of 
National TB Program (NTP) or in the CSDT, where the 
test was available; the UCK does not have this tool. Due 
to the rarity of children with MDR-TB, we included all 
the MDR-TB cases registered over the study period.  
For all cases, we collected a specimen depending on the 
age of the patient and the form of TB. All cases relied 
on Xpert MTB-Rif for diagnosis (Xpert MTB/Rif; 
Cepheid, Sunnyvale, CA, USA), and the Ziehl test for 
follow up.  
The anamnestic parameters were collected concerning 
any history of TB or MDR-TB contact, BCG 
vaccination, number of persons in the house, number of 
pieces at the house, time between diagnosis and 
initiation of treatment, and symptoms at admission; 
symptoms, clinical and paraclinical signs; parameters of 
follow up; and outcomes. For all children, we obtained a 
specimen for diagnosis, either liquid of gastric 
aspiration for children under 6 years old or sputum for 
older children. The microscopy, Xpert MTB/Rif, chest 
X-ray, HIV test was performed for all included children. 
The Lowenstein culture was realized in 12 cases.   
The treatment was initiated as soon as the diagnosis was 
available. Treatment was conducted for 9 months. This 
treatment consist on 4 months of intensive phase and 5 
months of continuous phase treatments. When, at the 4
th
 
month of treatment, the microscopy test remained 
positive for the bacteriologic confirmed cases or when 
the clinical stabilization was not attend for the clinically 
diagnosed cases, the intensive phase was extended for 1 
additional month. The continuous phase was extended 
for 2 additional months when the clinical recovery was 
not obtained at the 9 months. Patients received 
Kanamycin (Kn), 15 mg/kilogram (kg) 5 days by week; 
Levofloxacin (LFX), 8 mg/kg; Prothionamide (Proth), 
15 mg/kg; Clofazimine (Clof), 5 mg/kg; INH, 10 mg/kg; 
Pyrazinamide, (Z) 30 mg/kg; and Ethambutol (E), 20 
mg/kg, for the intensive phase, and LFX, Clof, Z and E 
at the same dosages for the continuous phase. These 
drugs have been used previously in other cohorts around 
the world 
6, 7, 8
. The treatment was given early in the 
morning once per day. After treating any emergency 
conditions, the TB treatment was followed by 
ambulatory care, given by an adult who received 
appropriate instructions. This adult could be a parent or 
a tutor or a nurse. However, a nurse was required for the 
injectable drug. There were no pediatric formulas, and 
the tablets were broken and/or crushed as necessary to 
obtain correct dosages and available presentation for 
administration to the children. For small children, tablets 
were dissolved with water before administration. 
Injectable drugs were given in the buttocks in the 
superior and external quarters.  
The follow up was planned for 1 week after the 
initiation of treatment, in each month for the intensive 
phase, and every 3 months for the second phase. For the 
positive cases identified by Xpert MTB-Rif, the control 
was determined each month until there was conversion 
of the Ziehl test result. The objective of the first 
appointment was to verify the tolerance of and 
adherence to the treatment and to provide psychological 
support to the children and/or their parents. At the initial 
and subsequent appointments, the tolerance and 
adherence were verified, and an assessment of adverse 
effects was made. The hemogram, transaminases, 
creatinine, uric acid, electrocardiograph and ionogram 
were performed for each control, and the auditory acuity 
was determined. When a child missed an appointment, a 
nurse was sent to the home to ask about the absence and 
explain again the necessity of follow up.  
The data were analyzed with SPSS version 20.2 
software. Frequencies and medians (with confidence 
interval) were reported as absolute numbers and as 
percentages. The Fisher test was realized to compare 
some data.  
The ethics committee of the Public Health School of the 
University of Kinshasa approved the study 
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(ESP/CE/042B/2015). The formal consent of the parents 
or tutors was obtained prior to inclusion of each child in 
the study. The study was conducted in accordance with 
the standards defined by the Declaration of Helsinki. 
There were no conflicts of interest. The authors did not 
receive any funding for this study.     
RESULTS      
A total of 33 cases were registered at the Pneumology 
service of UCK; 8 were diagnosed by Xpert before their 
transfer to UCK and 25 had a suspicion of MDR-TB. 
Among the suspicious cases, 12 (48%) were excluded 
because, after analysis, they were found to have other 
diagnoses (4 cases of lymphoma, 2 cases of pulmonary 
tumors, 3 cases of non-specific pneumonia, 2 cases of 
non-specific pleural effusion, and 1 case of 
bronchiectasis). Twenty-one cases were ultimately 
included in the study: 11 (52.38%) were males and 10 
(47.62%) were females, resulting in a sex ratio of 1.1. 
The median age was 9.6 years (minimum, 2 weeks; 
maximum, 15 years). Fifteen (71.43%) cases were 
confirmed by Xpert MTB-Rif (between them 11 had a 
positive Ziehl test and 2 had a positive Lowenstein 
culture), and 6 (28.57%) cases had MDR-TB contact 
and suggestive radiologic lesions. The recruitment of 
cases is detailed in Figure 1. [Figure 1]  
The most frequent symptoms at inclusion were 
persistent fever (21 cases, 100%), persistent cough (17 
cases, 80.95%), weight loss (15 cases, 71.43%), 
vomiting (10 cases, 47.61%) and dyspnea (9 cases, 
42.85%). Concerning the form of TB, 15 cases (71.43%) 
had PTB and 6 (28.57%) had EPTB (3 pleural effusion, 
2 lymph node TB, and 1 meningitis TB). Concerning 
radiologic findings, in 9 (42.85%) cases, patients had 
more than 1 type of lesion. There was an alveolar 
syndrome in 8 cases, pleural effusion in 5 cases, 
mediastinal lymph node involvement in 7 cases, cavities 
in 3 cases, interstitial infiltration in 2 cases, miliary 
pattern in 2 cases, fibrosis in 2 cases, and atelectasis in 1 
case. Two cases had co-infection with Human 
Immunodeficiency Virus (HIV). All 21 cases were 
analyzed by the Xpert-MTB-Rif test, and 15 tested 
positive as Xpert MTB-Rif resistant. Table I shows the 
demographic and clinical results. The Fisher test showed 
that the Ziehl conversion was significantly associated 
with outcome (p=0.001). [Table I]  
 
 
Legend: *UCK: University Clinic of Kinshasa; £CPLT: Kinshasa’s provincial coordination site for TB; MDR-TB®: Multidrug-
resistant tuberculosis; ₳AFB: acid-fast bacilli; ¥Rif: Rifampicin.  
Figure 1: Recruitment of cases 
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All patients received a 12 month short-course of second-
line treatment as described above. The time between 
diagnosis and the initiation of this treatment ranged from 
1 to 8 days. 
  
Table 1: Distribution of demographic, clinical and paraclinical characteristics and outcomes 






- 0-6 y (n=8) 









- Male (n=11) 









- Persistent cough (n=17) 








Form of TB 
- PTB (n=15) 









- Parenchymal lesions (n=22) 









- Xpert MTB/RIF confirmed (n=15) 








Ziehl test conversion(11 cases) 
- < 4 months of treatment (n=8) 








   *each patient could have one or more than one symptoms or radiologic lesion 
At follow up, the time to Ziehl test conversion was 
established between the 11 cases with Ziehl test positive 
at the initiation. The negativity on Ziehl testing appeared 
before or at 4 months of treatment in 8 cases (at 1 month 
for 3 cases, at 2 months for 2 cases, at 3 months for 2 
cases, and at 4 months for 1 case), at 5 months for 1 
case, at 6 months of treatment for 1 case, and at 8 
months for 1 case. The median period of Ziehl 
conversion was 3 months (IC: 1.91-3.56 months). The 
radiologic follow-up showed a resolution of signs 
between 2 to 9.5 months for almost all cases, except for 
2 cases who had chest X-ray lesions until the last month 
of treatment (for 1, a small pleural effusion; for the 
other, fibrosis). Adverse treatment effects included 
vomiting and stomach pain in 3 cases each (14.28%), 
scratching in 2 cases (9.52%) and urticarial rash in 1 
case (4.76%). Biologic surveillance noted high 
transaminase levels in 4 cases (19.04%, in 1 case more 
than 2 times the normal range) and high uricemia in 7 
cases (33.3%). All side effects were resolved by simple 
measures. For stomach pain, 2 patients received an anti-
vomiting and 1 patient received an anti-spasmodic. For 
scratching and urticarial rash, patients received an anti-
histaminic. For patients who showed high transaminase 
levels, INH was stopped for 2 weeks and reintroduced 
progressively. For patients who had a high level of 
uricemia, the dose of Z was reduced by 5 mg per kg of 
body weight, and for 1 case who had a persistently high 
level after this reduction, allopurinol was prescribed. In 
general, for all patients with side effects, the treatment 
was continued until the end, and the side effects were 
minimized.  
Concerning outcomes, 18 (85.71%) patients had a good 
outcome (11 were cured and 7 completed treatment), 
and 3 (14.28%) patients had a poor outcome (2 died and 
1 was lost to follow up). The first patient who died was 
5 years old; he was in the first month of treatment and 
had a co-infection with HIV and malnutrition. The 
second patient was 6 years old; he died during the 7
th
 
month of treatment, after he arrived at the hospital 2 
hours before his death with dyspnea resistant to oxygen, 
and he remained malnourished. The Lowenstein culture 
of this patient did not show growth. The lost case was 4 
years old; he had pneumonia with meningitis and 
disappeared from follow up in the fifth month of 
treatment. His control Ziehl test was negative at the 4
th
 
month. The visit at home noted that he traveled with his 
parents.   
DISCUSSION 
The main objective of the study was to describe the 
clinical profile and to assess the efficacy of a short 
course treatment in children with MDR-TB in a setting 
where TB is prevalent. This study revealed that 
childhood MDR-TB is a reality in the DRC, especially 
in Kinshasa. In this series, 21 cases were diagnosed with 
MDR-TB; 2 had co-infections with Human 
Immunodeficiency Virus (HIV). Fifteen (71.43%) cases 
were confirmed by Xpert MTB-Rif, and 6 (28.57%) 
cases were clinically diagnosed. Their common 
symptoms included persistent fever (100%), persistent 
cough (80.95%), weight loss (71.43%), vomiting 
(47.61%) and dyspnea (42.85%); their clinical forms 
were PTB (15 or 71.43%) and EPTB (6 or 28.57%), of 
which 3 had pleural effusion, 1 had meningitis TB, and 
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1 had lymphadenitis. The treatment outcomes were 
good: 85.71% had good outcome (11 cured and 7 
completed treatment), and 3 (14.28%) had a poor 
outcome (2 died and 1 lost was lost to follow up). The 
treatment was generally well-tolerated; there were 3 
cases of vomiting and stomach pain, 3 skin reactions, 4 
elevations of transaminases and 7 elevations of 
uricemia.  
MDR-TB is a formidable TB infection that poses a 
major challenge to the global control of the disease. It is 
underestimated in children because of the non-specific 
clinical symptoms and the difficulty in confirming the 
diagnosis 
10
. A definitive diagnosis of MDR-TB must 
include a microbiological diagnosis 
11
. These difficulties 
are likely reasons why the number of MDR-TB cases 
was low in this study. It appears important to analyze all 
children with contact with MDR-TB patients and to 
carry out home visits to new adult MDR-TB cases to 
identify children with prevalent TB 
12
. It is essential to 
find MDR-TB cases because it has been shown that 80-
90% of children with MDR-TB are usually 
contaminated by a close, infected adult 
13
. Population 
education, especially maternal education, must be 
provided to improve knowledge of TB 
14
 so that all 
children with MDR-TB contacts will be brought to a 
care facility for early examination for MDR-TB.    
In this study, 28.5% of patients had EPTB. It is incorrect 
to think that MDR-TB can present with only pulmonary 
involvement. In 2014, in Madrid, Santiago B et al 
showed an association between MDR-TB and EPTB 
15
. 
In China in 2016, Qian Guo et al, in a cross-sectional 
study of 196 pediatric cases of mycobacterial culture-
confirmed TB, found 44.4% of cases with exclusively 
thoracic TB, 41.8% of cases with thoracic-extrathoracic 
TB, and 13.8% of cases with exclusively extrathoracic 
TB 
16
. Extrathoracic TB is more frequently encountered 
in children than in adults 
17
. It is important to obtain 
biological specimens from any suspected anatomic sites 
for TB from any suspected MDR-TB case, especially in 
children 
16
. The opportunity to examine any biological 
specimen with Xpert-MTB/Rif can facilitate diagnosis 
in children who have difficulty in providing sputum for 
analysis 
16
. Old techniques however, like culture in 
Lowenstein Jensen medium, can also provide a 
diagnosis of MDR-TB 
18
.  
MDR-TB treatment must be initiated immediately after 
diagnosis to improve the outcome and reduce the risk of 
transmission 
12
. In this study, treatment was delayed for 
several cases for 1 week because the drugs needed to be 
provided from another site, especially by the NTP. The 
university hospital does not maintain stocks of these 
drugs.  
The WHO has proposed total treatment duration of 20 
months or more, with an 8-month intensive phase, for 
MDR-TB patients 
19
. However, this treatment is 
associated with low compliance because of the long 
duration, the high number of drugs to take, significant 
adverse effects, and stress with injectable drugs, 
especially for children. The low compliance has an 
impact on the treatment outcome 
20
. The incidence of 
side effects is also important because of the immaturity 
of children’s biological systems, and the misrelating of 
their early side effects can also justify the preference of 
short-course treatment in children. In the present study, 
we therefore used a short-course treatment.  
Studies conducted around the world with short-course 
treatments (9 to 12 months of treatment) have shown a 
lower cost, a better tolerance, and a better compliance, 
contributing to a better efficacy 
6, 7, 8, 21, 22, 23
. The short-
treatment uses more efficient drugs for Mycobacterium 
tuberculosis (MT), such as the fourth-generation 
quinolone Gatifloxacin, LFX, or Moxifloxacin, Clof, 
and a high dose of INH or Bedaquilline 
6, 24, 25
.   
Here, we used Clof and high doses of INH and LFX. 
The choice of LFX in this study was due to the early 
bactericidal activity of this drug in MT, which is slightly 
higher than for Gatifloxacin, and lower cardiac effects 
than Moxifloxacin 
24, 25
. In the present study, the 
treatment outcome was good (85.7%), and the tolerance 
of treatment was acceptable because there were no 
major side effects.    
In the present study, after stabilization of patients in the 
hospital, the treatment was continued by ambulatory 
care. For the first 6 months of treatment, patients 
attended the hospital or a care facility near their home 
for the injection of KM; the rest of the treatment was 
administered at home. There are no available facilities in 
the University Hospital of Kinshasa to admit MDR-TB 
patients because there is no controlled airway or 
aspiration system. Thus, the treatment was administered 
by ambulatory care, especially after the end of the 
injection drug treatments. The outcomes of patients 
were good; only 1 patient was lost to follow up. 
Ambulatory care for the treatment of MDR-TB has also 
been used in Ethiopia with good results 
26
.  
In TB-prevalent countries, many challenges can delay 
the achievement of the “End TB” objectives. Among 
these challenges, research on MDR-TB in children is a 
priority 
27
. There is a need to provide access to new 
MDR-TB drugs, especially for children 
28
. 
This study is the first in the DRC to use a short-course 
treatment in children for MDR-TB. The results showed 
that this treatment is feasible, efficacious, and well-
tolerated by children. The limit of this study is the need 
for a comparison with a longer one, which is not 
available for the moment in our context.  
CONCLUSION  
MDR-TB remains a challenge in children. The treatment 
must be initiated immediately after diagnosis to improve 
the outcome. A short treatment course is evaluated in 
children in DRC, showed a therapeutic success rate in 
85.71%. The treatment was comfortable in the majority 
of cases. More cases are needed to have a longer cohort 
in order to better evaluate this treatment. 
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